12:00 AM
 | 
Oct 16, 2006
 |  BC Week In Review  |  Company News  |  Other News

Astralis autoimmune, dermatology news

ASTR said it will discontinue its drug development activities and is considering strategic alternatives, including selling its assets. In August, the company said its liabilities had exceeded its cash,...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >